Last quarter (Q4 2022), Oncimmune Holdings's total revenue was £―, a decrease of ― from the same quarter last year. In Q4, Oncimmune Holdings's net income was £―. See Oncimmune Holdings’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Aug 22	May 22	May 21	May 20	May 19
Total Revenue	-	£ 3.79M	£ 3.86M	£ 3.72M	£ 509.00K	£ 171.00K
Cost of Revenue	-	£ 1.96M	£ 2.40M	£ 865.00K	£ 537.00K	£ 1.03M
Gross Profit	-	£ 1.83M	£ 1.46M	£ 2.86M	£ -28.00K	£ -859.00K
Operating Expense	-	£ 12.28M	£ 10.04M	£ 8.31M	£ 9.86M	£ 7.73M
Operating Income	-	£ -10.46M	£ -8.59M	£ -5.46M	£ -9.88M	£ -8.59M
Net Non Operating Interest Income Expense	-	£ -1.51M	£ -943.00K	£ -951.00K	£ -515.00K	£ 41.00K
Other Income Expense	-	£ -411.00K	-	-	-	-
Pretax Income	-	£ -11.56M	£ -9.53M	£ -5.70M	£ -9.78M	£ -8.55M
Tax Provision	-	£ -173.00K	£ -17.00K	£ -1.07M	£ -1.32M	£ -536.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -11.39M	£ -9.51M	£ -4.63M	£ -8.46M	£ -8.01M
Basic EPS	-	£ -0.16	£ -0.14	£ -0.07	£ -0.13	£ -0.13
Diluted EPS	-	£ -0.16	£ -0.14	£ -0.07	£ -0.13	£ -0.13
Basic Average Shares	-	£ 69.03M	£ 69.43M	£ 64.57M	£ 63.30M	£ 61.78M
Diluted Average Shares	-	£ 69.03M	£ 69.43M	£ 64.57M	£ 63.30M	£ 61.78M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	£ 0.13
Reported Normalized Diluted E P S	-	-	-	-	-	£ 0.13
Rent Expense Supplemental	-	-	-	-	-	£ 146.00K
Total Expenses	-	£ 14.25M	£ 12.45M	£ 9.18M	£ 10.39M	£ 8.76M
Net Income From Continuing And Discontinued Operation	-	£ -11.39M	£ -9.51M	£ -4.63M	£ -8.46M	£ -8.01M
Normalized Income	-	£ -11.73M	£ -9.51M	£ -4.88M	£ -8.99M	£ -8.01M
Interest Expense	-	-	£ 943.00K	£ 837.00K	£ 314.00K	£ 11.00K
EBIT	-	£ -10.48M	£ -8.59M	£ -4.86M	£ -9.47M	£ -8.54M
EBITDA	-	£ -8.84M	£ -7.16M	£ -4.12M	£ -8.97M	£ -8.30M

Currency in GBP

Oncimmune Holdings Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing